Collegium Pharmaceutical (COLL)
(Delayed Data from NSDQ)
$38.44 USD
-0.49 (-1.26%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $38.43 -0.01 (-0.03%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth F Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$38.44 USD
-0.49 (-1.26%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $38.43 -0.01 (-0.03%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth F Momentum A VGM
Zacks News
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?
by Zacks Equity Research
Here is how Context Therapeutics Inc. (CNTX) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.
Collegium Pharmaceutical (COLL) Upgraded to Buy: Here's Why
by Zacks Equity Research
Collegium Pharmaceutical (COLL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Collegium Pharmaceutical (COLL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 3.85% and 1.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Unveiling Collegium Pharmaceutical (COLL) Q2 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Collegium Pharmaceutical (COLL), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium Pharmaceutical (COLL) Soars 10.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Collegium Pharmaceutical (COLL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -2.68% and 1.44%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Unlocking Q1 Potential of Collegium Pharmaceutical (COLL): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Collegium Pharmaceutical (COLL), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 55.56% and 5.80%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium (COLL) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Collegium's (COLL) top line is likely to have been fueled by growth in the sales of pain drugs, Belbuca and Xtampza ER, in the first quarter of 2024.
Collegium Pharmaceutical (COLL) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Collegium Pharmaceutical (COLL) closed at $38.79 in the latest trading session, marking a -1.6% move from the prior day.
Humana (HUM), DUOS Unveil Program to Improve Veterans' Health
by Zacks Equity Research
Humana (HUM) collaborates with DUOS to develop a program that aims to provide personalized care and assure the well-being of Louisiana's Veteran community, who have a HUM MA plan and suffer from chronic conditions.
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks.com featured highlights AppLovin, Kaiser Aluminum, Collegium Pharmaceutical, EMCOR Group and Textron
by Zacks Equity Research
AppLovin, Kaiser Aluminum, Collegium Pharmaceutical, EMCOR Group and Textron have been highlighted in this Screen of The Week article.
Strength Seen in Aquestive Therapeutics (AQST): Can Its 16.0% Jump Turn into More Strength?
by Zacks Equity Research
Aquestive Therapeutics (AQST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Time to Get These 5 Top Relative Price Strength Stocks
by Nilanjan Choudhury
APP, KALU, COLL, EME and TXT are five stocks with explosive relative price strength.
3 Reasons Why Collegium Pharmaceutical (COLL) Is a Great Growth Stock
by Zacks Equity Research
Collegium Pharmaceutical (COLL) could produce exceptional returns because of its solid growth attributes.
Encompass Health (EHC), Piedmont to Build Loganville Facility
by Zacks Equity Research
Encompass Health (EHC) partners with Piedmont to construct a 40-bed inpatient rehabilitation hospital in Georgia to better serve the rehabilitative care needs of the state and solidify its footprint.